All News
EULAR 2021 – Day 4 Report
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
Read Article
RheumNow Podcast - Best of EULAR 2021
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read Article
Israel provides COVID vaccine answers for rheumatic disease patients
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
Read Article
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheums’ offices everywhere this year, and at #EULAR2021, data presented from Israel, has provided much-needed answers.
https://t.co/PUa6deflTy https://t.co/cs4MwnIcdR
Links:
Dr. John Cush RheumNow ( View Tweet)
Mavrilimumab (GM-CSFi) phase II trial of COVID-19 PNA and systemic hyperinflammation
⭐️65% risk reduction in ventilation/death
⭐️no sig difference in ventilation requirement
⭐️no serious AE
Abs#LB0001
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
This is by far the biggest rheum dx COVID vaccinated cohort described I'm aware of 👏
Looking forward to full paper, & we will need data with more pts, more details, cellular response etc.
Nevertheless, invaluable & reassuring.
So glad to see it at #EULAR2021 LB0003 @RheumNow https://t.co/jsHZjLdCTT
David Liew drdavidliew ( View Tweet)
6. Rheum disease activity was stable with COVID vaccination.
(RA, PsA, axSpA, SLE - total n = 597)
7/
LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew drdavidliew ( View Tweet)
Israel was early to COVID vaccinate on mass scale. How well did the vaccine work in their rheum dx pts?
rheum pts n=686 (vs controls n = 121)
- fewer w immunogencity, but not bad (86% vs 100%)
- safety good
- dx activity stable
more details below ⬇️
LB0003 #EULAR2021 @RheumNow https://t.co/h2WT404mkF
David Liew drdavidliew ( View Tweet)
Reassuring safety data from @rheum_covid COVAX registry on #COVID #vaccination in patients with #RMDs
👉🏼Vaccine welltolerated by most patients
👉🏼Most adverse events similar to gen population
👉🏼RMD flares were rare after vaccine
👉🏼#GetVaccinated!
LB0002 @pedrommcmachado #EULAR2021 https://t.co/bheIcVZ9xa
Mrinalini Dey DrMiniDey ( View Tweet)
Would you use #Telemedicine (TM) to follow-up #SLE patients post #COVID? Dr So showed in an RCT (N=122),patient satisfaction and time-to-review were better in TM vs Face-to-Face. Although none had COVID, >pts in TM were hospitalised and trend to⬆️FU #EULAR2021 #POS1164 @RheumNow https://t.co/p7aWv4AVm7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2021 OP0291 proposes focus score of 4+ as prognostic factor for lymphoma risk in Sjogrens
Focus score 4+:
⬆️lymphoma risk
⬆️salivary gland swelling
⬆️autoantibodies
⬇️thyroiditis
Authors propose 4yr follow-up biopsy in all pts Focus score 4+.
@RheumNow
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 LB0001. Mavrilimumab (blocks GM-CSF alpha) phase2 trial in non-vented patients w/ #COVID19 :
⭐️⬇️ mortality and ventilation at day 29
⭐️61% reduction in death (HR 0.39)
⭐️No drug related SAEs, no dose-related AEs
@Rheumnow https://t.co/9UOi3xF7Re
Eric Dein ejdein1 ( View Tweet)
#EULAR2021 LB0002 #COVID vax safety in RMD
⭐️78% received Pfizer, 16% Astra Zeneca
⭐️5% of pts flares, 1.2% severe flares
⭐️31% had vax side effects, 0.1% severe AEs
Side effect profile similar to gen population. Good data for uncertain patients!
@RheumNow @rheum_covid https://t.co/PGZcph9Mu6
Eric Dein ejdein1 ( View Tweet)
What’s the biggest reason for vaccine hesitancy in your patients? @RheumNow #EULAR2021
Eric Dein ejdein1 ( View Tweet)
#EULAR LB0003 Pfizer #COVID vax immunogenicity and safety in 686 rheum pts in Israel
⭐️Sero+ for COVID Ab 86% in RMD vs 100% controls
⭐️RTX lowest seropos of 39%, related to time of infusion
⭐️⬇️ with GC, ABA, MMF
⭐️ MTX not seen to significantly ⬇️
@RheumNow @rheum_covid
Eric Dein ejdein1 ( View Tweet)
Even when we go outright looking for COVID vaccine-related problems in rheum disease patients, we really don't find much.
Get your rheumatology patients vaccinated!
reassuring from @eular_org COVAX registry, thanks to all involved! @pedrommcmachado LB0002 #EULAR2021 @RheumNow https://t.co/mIBeglQ5KS
David Liew drdavidliew ( View Tweet)
COVID-19 Global Rheum Alliance Registry: prediction of ARDS by machine learning algorithm in a model using 42 variables including:
demographics, rheumatic D, meds and comorb with Sens 0.81, Spe 0.49, AUC 075. Interesting model for close monitoring #OP0288 @Rheumnow #EULAR2021 https://t.co/9YY0jzDx59
Aurelie Najm AurelieRheumo ( View Tweet)
Presenting now at #EULAR2021
#COVID19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with #rituximab: a cohort study
https://t.co/QTGkiMcC2d https://t.co/DJB6GooPuJ
Links:
The Lancet Rheumatology TheLancetRheum ( View Tweet)
wonder if vit D is a surrogate for poor health, low SES, diet? In #SARSCoV2 infection low vit D has worse outcomes but clusters racially (⬇️ by skin tone) & seems related to SES. But perhaps adding vit D can help immune system & be anti-inflammatory #EULAR2021 @RheumNow POS0100 https://t.co/TEf52bLs0i
Janet Pope Janetbirdope ( View Tweet)
Zara Izadi presents @rheum_covid data on machine learning algorithms to predict ARDS in RMD patients with COVID. Gradient boosting machine had 81% sensitivity to predict ARDS from baseline data @RheumNow #EULAR2021 Abstr#OP0288 https://t.co/tHlPzeX9He
Richard Conway RichardPAConway ( View Tweet)
